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Abstract
Background: Good adherence to ocular hypotensive agents is important to control intraocular pressure and hence
to prevent progressive glaucomatous optic nerve head damage. Periodic investigation of adherence is crucial in
glaucoma treatment. The purpose of this study was to assess level of adherence to ocular hypotensive agents and
to identify factors affecting adherence among glaucoma patients at a tertiary public eye care center.
Methods: The study was a hospital-based cross-sectional study that was conducted in Menelik II Referral Hospital
from June 1, 2015 to July 31, 2015. A systematic random sampling technique was used to select 359 study participants
from the source population. The study patients were interviewed and their medical charts were reviewed using a
pretested structured questionnaire. Adherence was assessed using Morisky Medication Adherence Scale - 8 and
adherence determinant factors were identified using multivariate binary logistic regression analysis. The association was
declared statistically significant at p < 0.05.
Results: Among the 359 study glaucoma patients, 42.6 % were adherent to their prescribed hypotensive agents.
Higher educational level (AOR = 4.60, 95 % CI: 1.01–21.03, p < 0.049), being self - employed (AOR = 6.14, 95 % CI:
1.37–27.50, p < 0.018) and taking lesser frequency of drops (AOR = 2.89, 95 % CI: 1.25–6.66, p < 0.013) were significantly
associated with adherence, whereas being a farmer (AOR = 0.07, 95 % CI: 0.01–0.75, p < 0.028), having very low monthly
family income (AOR = 0.22, 95 % CI: 0.06–0.77, p < 0.019) and self - purchasing of medications (AOR = 0.30, 95 % CI:
0.10–0.93, p < 0.036) were significantly associated with non-adherence.
Conclusions: The study has identified the adherence level to the prescribed ocular hypotensive agents to be
sub-optimal and is influenced by different factors among glaucoma patients of the public tertiary center. We
recommend glaucoma care providers to pay due attention on the importance of adherence.
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Background
Glaucoma is a progressive optic neuropathy which is
caused by the death of the retinal ganglion cells and
their fibers [1, 2]. It is a public health problem in devel-
oping countries, chiefly in sub-Saharan Africa, which is
further compounded by poor awareness and low know-
ledge of glaucoma patients towards the disease [3, 4].
Adherence is the extent to which a patient’s behavior
in taking medication corresponds with agreed recom-
mendations from the provider [5]. Glaucoma medica-
tions are used over a long period or life-long that
require long-term adherence to achieve the maximum
intraocular pressure (IOP) lowering effect and prevent
further progression of the disease [1, 6]. The major de-
terminant for success in medical therapy of glaucoma
is, therefore, the adherence of patients to their medica-
tions [7, 8].
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Studies have documented that non-adherence is a sig-
nificant problem among glaucoma patients which is fur-
ther influenced by the asymptomatic nature of the
disease [9, 10]. Reported adherence varies widely in dif-
ferent glaucoma studies [10] but a systematic review of
31 studies reported that 25 % of patients were found to
be non-adherent [11]. Non-adherence potentially results
in treatment failure, which is manifested as persistent
elevation of IOP which, in turn, leads to progressive
optic nerve damage and deterioration of the visual field
[12–14]. Non-adherence is also associated with unneces-
sary prescription of drugs which add an extra burden on
the health economy [15].
Glaucoma medication adherence could be measured
through self-report, pharmacy refill reports, electronic
monitoring and direct observation. To be clinically rele-
vant, an ‘acceptable’ adherence level should be deter-
mined by its impact on clinical outcome [10]. Such
evidence is lacking for ocular hypotensive agents due to
the requirement for long-term follow-up and known in-
accuracies in determining IOP control, visual field de-
fects or optic nerve damage [16]. In the absence of any
pre-existing gold standard measure, adherence to ocular
hypotensive agents was measured using the Morisky
Medication Adherence Scale – 8 (MMAS – 8) in this
study [17]. The main purpose of this study was, there-
fore, to assess the level of adherence to ocular
hypotensive agents and its determinant factors among
glaucoma patients at a tertiary public referral hospital.
Methods
A hospital-based cross-sectional study was conducted at
the glaucoma clinic of Menelik II Referral Hospital,
Ethiopia from June 1, 2015 to July 31, 2015. At the
clinic, glaucoma diagnosis was made based on the pres-
ence of elevated IOP (>20 mmHg), gonioscopy findings,
characteristic optic nerve head damage (vertical cup-disc
ratio greater than 0.4; diffuse or focal thinning or notch-
ing of the neuroretinal rim; or presence of asymmetry of
the vertical cup-disc ratio of 0.2 between eyes) and/or
visual field defect. The source population for this study
was all glaucoma patients who received services at the
glaucoma clinic of the hospital and the study population
was all glaucoma patients who obtained services during
the study period at the clinic.
Sample size determination and sampling technique
The sample size was calculated using a formula used to
estimate the sample size for a single population [18].
Considering 1.96 for the standard normal variable with
5 % level of significance (α - value), 95 % confidence
interval, 5 % margin of error and 10 % contingency, the
sample size was calculated to be 359 from the 2120
study population. A systematic random sampling
technique was employed to select the samples from the
study population. The sampling interval was calculated
to be 2120/359 = 6. A starting point was chosen ran-
domly from numbers 1 to 6 and hence eligible individ-
uals were chosen every sixth client at regular interval
from the sampling frame.
Recruitment of research participants
Glaucoma patients enter the clinic’s triage and make a
queue in the waiting area. The ophthalmic nurses meas-
ure both visual acuity and IOP and register these find-
ings on the patient’s chart prior to getting services from
physicians. While the patients were waiting at a waiting
area during their appointment day, patients were
screened for eligibility based on the inclusion and exclu-
sion criteria. The study participants, who were selected
from the sampling frame, were briefed about the pur-
pose of the study and then requested for willingness for
an interview at a nearby separate room.
Inclusion and exclusion criteria
Patients who were 18 years old and above, with the diag-
nosis of glaucoma or ocular hypertension, were on ocu-
lar hypotensive agents for one or both eyes for at least
6 months, had regular follow-up and had not undergone
either laser or glaucoma surgery in the previous
3 months were enrolled in the study. Glaucoma patients
with post-operative follow-up, on systemic glaucoma
drugs only, on anti-inflammatory or anti-infective eye
drops only, who were not willing to give informed writ-
ten consent and those enrolled in the pretest were ex-
cluded from the study.
Data collection and analysis
Data were collected by three trained ophthalmic nurses
through a face-to-face interview to collect socio-
demographic characteristics (age, sex, educational level,
residence, and occupation), medication-related charac-
teristics (number, type, and side effects of medications)
and adherence level. Medical charts of the patients were
reviewed to abstract the type and severity of glaucoma,
and visual acuity. Adherence to ocular hypotensive
agents was measured using MMAS–8 which is a
medication-taking behavior scale. MMAS–8 is the latest
version of the scale and has a good internal consistency
(Cronbach’s α = 0.83) [17]. This scale has been used for a
wide variety of chronic medical conditions [19]. The
study participant was deemed to be adherent when the
MMAS – 8 score was < 2 and non-adherent when the
MMAS – 8 score was ≥ 2 [20].
The questionnaire was translated to Amharic, a na-
tional language, and then translated back to English. To
maximize quality of the data, the tool was pre-tested in
5 % of the study subjects (18 patients). The filled-in
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forms were checked for completeness of data and
cleaned prior to data entry. Data were entered using Epi
Info™ version 3.5.3. Data analysis was carried out using
Statistical Package for Social Sciences (SPSS®Statistics)
program version 21 (Chicago, IL, U.S.A.). Descriptive
statistics such as frequency, percentage, mean and stand-
ard deviation were also employed to summarize patient’s
characteristics.
Univariate binary logistic regression analysis was per-
formed to assess the association of the variables to ad-
herence. From the result of the univariate analysis,
variables with p < 0.2 were selected for multivariate bin-
ary logistic regression analysis which was used to assess
factors affecting adherence and to estimate the odds ra-
tios (OR), 95 % confidence intervals (CI) and p - values.
The association was declared statistically significant at
p < 0.05.
Results
The socio-demographic and clinical characteristics of
the study participants are summarized in Table 1.
Among 359 eligible patients, about half of the patients
(n = 181, 50.4 %) were in the age group of 61–80 years
old (mean: 60.91, SD ± 12.34 years; range: 18 to 88 years).
Large number of the patients were males (n = 247,
69.0 %). Concerning the educational level, 229
(63.9 %) patients had a lower education (elementary
school and/or below). Majority of the study subjects
were residing in urban areas (n = 322, 89.7 %) and
about one-third (n = 115, 32.0 %) of the patients were
retired (Table 1).
According to the medical records of the patients, the
most prevalent type of glaucoma diagnosis was pseudoexfo-
liative glaucoma which accounted for 40.5 % (n = 138)
followed by primary open angle glaucoma (n = 93, 27.3 %).
The stage of glaucoma, based on the Canadian glaucoma
strategy classification [21], was recorded as early, moderate
and advanced in 32 (11.9 %), 173 (64.1 %) and 65 (24.1 %)
patients respectively (Table 1).
Almost all (n = 350, 97.5 %) of the patients were
using one and/or two medications as depicted in
Table 2. The combination of eye drops accounted for
about half (n = 185, 51.5 %) of the prescribed medica-
tions followed by timolol as a monotherapy (n = 158,
44.0 %). Regarding eye drop administration, 123
(32.8 %) patients admitted that they were waiting more
than five minutes to administer the second or con-
secutive drop. Above half (n = 200, 56.0 %,) of the pa-
tients also reported that they did not experience side
effects (such as redness, itching, burning and blurring
of vision) immediately after starting the medications
(Table 2). According to the international council of
ophthalmology’s classification of visual acuity [22],
about one-third of the patients had (near-) normal
vision (n = 122, 34.3 %), low vision (n = 130, 36.6 %)
and (near-) blindness (n = 115, 32.3 %) on the better
eye (Fig. 1). Regarding the level of adherence, assess-
ment of patients’ response to the MMAS-8 revealed
that 42.6 % (n = 153) of the study patients were adher-
ent to their glaucoma medications (Fig. 2 and Table 3).
The results of logistic regression analysis for factors
associated with medication adherence are summarized
in Table 4. Variables with p - value less than 0.2 (mari-
tal status, educational level, occupation, monthly
Table 1 Socio-demographic and clinical characteristics of study







≥ 81 7 1.9
Sex (n = 358)
Male 247 69.0
Female 111 31.0
Educational level (n = 358)
Illiterate or non-formal education 109 30.4
Elementary school (grade 1–8) 120 33.5
High School (grade 9–12) 73 20.4
Diploma and/or above 56 15.6







Employee (paid work) 79 22.0
Self-employed (merchant) 34 9.5
Other(s) (student, unemployed, prisoner) 79 22.0
Types of glaucoma (n = 341)
Pseudoexfoliative glaucoma 138 40.5
Primary open angle glaucoma 93 27.3
Primary angle closure glaucoma 48 14.1
Other(s) (normal tension glaucoma, secondary
glaucoma, ocular hypertension, juvenile
glaucoma)
62 18.2
Severity of glaucoma (n = 270)
Early glaucoma 32 11.9
Moderate glaucoma 173 64.1
Advanced glaucoma 65 24.1
Mehari et al. BMC Ophthalmology  (2016) 16:131 Page 3 of 8
family income, follow-up, number of medications, type
of medications, frequency of eye drop, time elapsed to
administer the second drop, side effects, purchasing of
the medications, and getting information about eye
drop administration from the physicians) were
incorporated into the multivariate logistic regression
analysis (Table 4).
In this study, educational level, occupation, monthly
family income, the frequency of eye drops and financial
source to obtain the medications were found to be po-
tential predictors of adherence to ocular hypotensive
agents. Accordingly, the odds of being adherent for pa-
tients with higher educational level (diploma and/or
above) were nearly five-fold (AOR = 4.60, 95 % CI: 1.01–
21.03, p < 0.049) more compared to patients with lower
educational status (Grade 1–8).
The odds of being adherent for farmer patients were
93 % (AOR= 0.07, 95 % CI: 0.01–0.75, p < 0.028) less com-
pared to patients who were retired. In contrary to this, pa-
tients who were self-employed were approximately six-fold
(AOR= 6.14, 95 % CI: 1.37–27.50, p < 0.018) more odds of
being adherent compared to those participants who were
retired. The odds of being adherent for patients with
very low monthly family income were 78 % (AOR = 0.22,
95 % CI: 0.06–0.77, p < 0.019) less compared to patients
with high monthly family income. It was also found that
the odds of being adherent for patients who were taking
fewer daily doses (two times per day) were approximately
three-fold (AOR = 2.89, 95 % CI: 1.25–6.66, p < 0.013)
more compared to those who were taking more frequent
eye drops (four times per day). The odds of being adherent
for patients who bought the medications by themselves
were about 70 % (AOR = 0.30, 95 % CI: 0.10–0.93,
p < 0.036) less compared to patients who obtained
the medications free of charge.
Table 2 Medication-related factors of glaucoma patients




Two or more 185 51.5




Other(s) (dorzolamide, dorzolamide + timolol,
brimonidine, betaxolol)
13 3.6
Two or more combination of eye drops 185 51.5
Time elapsed to administer the second or consecutive drop (n = 183)
Immediately 11 6.0
1–5 min 49 26.8
5–10 min 54 29.5
> 10 min 69 37.7
























Level of visual acuity  
(Near-) normal vision (6/6 to 6/18)
(Near-) blindness (less than 1/60 to no light perception; counting finger in-front, light perception or
hand motion)
Fig. 1 Profile of visual acuity among patients attending the glaucoma clinic, Menelik II Referral Hospital
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Discussions
The study has assessed adherence to ocular hypotensive
agents among glaucoma patients in Menelik II Referral
Hospital. One hundred fifty-three (42.6 %) patients were
found to be adherent which was similar to other studies
that reported 40.0–45.0 % in USA [23–25]. This similar-
ity might be evident owing to the use of a questionnaire
for interviewing the patients. On the other hand, the
level of adherence was found to be lower than 56.0 % in
Greece [12], 72.1 % in Canada [26] and 72.7 % in Dutch
[27] but higher than 30.7 % in England [28]. The wide
variation might be partly attributable to inconsistency in
the definition of non-adherence, subjectivity and hetero-
geneity in the assessment methods as well as differences
in patient groups [29].
During multivariate logistic regression analysis, pa-
tients with higher educational level were more likely to
be adherent compared to patients with lower educa-
tional level. This finding was similar to studies done in
Canada [26], USA [30, 31] and Germany [32]. Patients
who are more literate might have an updated informa-
tion on the disease and its progression, and have a better
understanding of the importance of adherence to the
medications. On the other point, self-employed patients
were more likely to be adherent compared to retired pa-
tients as the former might afford the medications easily.
Moreover, retired patients are usually older than self-
employed patients and might have greater cognitive and
physical impairment associated with aging.
In contrary to the above, farmer patients were less
likely to be adherent compared to retired patients. This
could be illustrated as the majority of the farmers in de-
veloping countries like Ethiopia are illiterate with limited
knowledge of the disease and have lower economic
status.
Patients who applied eye drops less frequently were
more likely to be adherent compared to patients who ap-
plied eye drops more frequently which corresponded
with a previous study [12]. This is evident by the fact
that increased daily frequency of eye drop is associated
with increased complexity of the regimen. However,
more emphasis should be given to the clinical import-
ance of frequency of administration and available dosage
preparations.
Patients with low monthly income were less likely to
be adherent compared to patients with high monthly
income. This finding was related to a previous study
that revealed unaffordability considerably affects ad-
herence [33]. Besides this, patients who purchased
ocular hypotensive drops by themselves were less
likely to be adherent compared to patients who ob-





Level of adherence 
Adherent Non-adherent
Fig. 2 Level of adherence among patients attending the glaucoma
clinic, Menelik II Referral Hospital
Table 3 Glaucoma patients’ response to the eight-item Morisky
instrument, glaucoma clinic of Menelik II Referral Hospital
Morisky Medication Adherence Scale (MMAS-8) Frequency (%)
Response
Yes No
Do you sometimes forget to take your eye
drop(s)?
209 (58.2) 150 (41.8)
People sometimes miss taking their eye
drop(s) for reasons other than forgetting.
Thinking over the past 2 weeks, were there
any days when you did not apply your eye
drop(s)?
116 (32.3) 243 (67.7)
Have you ever cut back or stopped taking
your eye drop(s) without telling your doctor
because you felt worse when you took it?
19 (5.3) 340 (94.7)
When you travel or leave home, do you
sometimes forget to bring along your eye
drop(s)?
48 (13.4) 311 (86.6)
Did you take all your eye drop(s) yesterday? 323 (90.0) 36 (10.0)
When you feel like your eye pressure is under
control, do you sometimes stop taking your
eye drop(s)?
31 (8.6) 328 (91.4)
Applying eye drop(s) every day is a real
inconvenience for some people. Do you
ever feel hassled about sticking to your
treatment plan?
84 (23.4) 275 (76.6)
How often do you have difficulty remembering
to apply all your eye drop(s)?
Never/rarely 140 (39.0)




Cut off Frequency (%)
< 2 153 (42.6)
≥ 2 206 (57.4)
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reason might also be related to an affordability issue
of the medications.
In this study, age and sex of the participants were not
significantly associated with the medication adherence
during the multivariate logistic regression analysis. The
absence of a relationship between adherence and most
of the socio-demographic factors was supported by the
previous findings [12, 23, 27, 29, 32, 34]. The absence
of this association might be related to the characteris-
tics of patients. The patients in the present study had a
long history of glaucoma (for an average of 5.6 years)
and a long duration of taking medication (mean
duration of taking hypotensive agents was 5.35 years).
Therefore, demographic factors might have less in-
fluence on the adherence behavior of the study
participants.
Multivariate analysis of this study also indicated that
medication adherence was not significantly associated
with the type and severity of glaucoma, side effects (even
though side effects were reported most commonly
amongst those who were non-adherent), duration of
glaucoma diagnosis, obtaining information about drug
administration, intraocular pressure, and visual acuity.
These results were comparable with different studies
[12, 27, 33–35]. It remains unclear whether these clinical
parameters might influence the adherence behavior of
glaucoma patients in general.
The study had certain limitations. The cross-sectional
nature of the study did not allow a follow-up, which
could have provided a better design for identifying the
factors associated with adherence. The results were also
relied on patients’ response. It is known that patients
tend to overestimate their ability to adhere to their ther-
apy which necessities further objective assessment tools
such as electronic medication monitoring system or bio-
logical assays in the future.
Table 4 Multivariate logistic regression analysis of factors associated with medication adherence among patients attending the
glaucoma clinic, Menelik II Referral Hospital
Variables Adherence COR (95 % CI) AOR (95 % CI)
Non-adherent, n (%) Adherent, n (%)
Educational level
Illiterate 67 (61.46) 42 (38.54) 1.01 (0.59, 1.72) 2.07 (0.53, 8.13)
Elementary School 74 (61.66) 46 (38.34) 1.00 1.00
High School 38 (52.05) 35 (47.95) 1.48 (0.82, 2.67) 1.87 (0.48, 7.26)
Diploma & above 26 (46.42) 30 (53.57) 1.86 (0.98, 3.53) 4.60 (1.01, 21.03)*
Occupation
Retired 66 (57.39) 49 (42.61) 1.00 1.00
Farmer 17 (73.9) 6 (26.1) 0.48 (0.16, 1.29) 0.07 (0.01, 0.75)*
House wife 18 (62) 11 (38) 0.82 (0.36, 1.90) 4.40 (0.82, 23.49)
Employee 42 (53.16) 37 (46.84) 1.19 (0.67; 2.11) 2.40 (0.70, 8.21)
Self-employed 16 (47) 18 (53) 1.52 (0.70, 3.27) 6.14 (1.37, 27.50)*
Other(s) 47 (59.5) 32 (40.5) 0.92 (0.51, 1.64) 0.763 (0.15, 3.86)
Monthly family income
Very low (<445 ETB) 59 (61.45) 37 (38.55) 0.82 (0.49, 1.37) 0.22 (0.06, 0.77)*
Low (446–1200 ETB) 90 (56.6) 69 (43.4) 1.71 (0.78, 3.75) 0.91 (0.18, 4.57)
Average (1201–2500 ETB) 31 (62) 19 (38) 0.80 (0.42, 1.53) 0.31 (0.10, 1.96)
Above average (2501–3500 ETB) 13 (54.16) 11 (45.84) 0.47 (2.61,0.00) 0.62 (0.14, 2.71)
High (>3501 ETB) 13 (43.33) 17 (56.67) 1.00 1.00
Frequency of eye drop
2 Times per day 3 (75.0) 1 (25.0) 1.85 (0.88, 3.91) 2.89 (1.25, 6.66)*
3 Times per day 35 (67.3) 17 (32.7) 1.27 (0.13, 12.8) 1.77 (0.17, 18.26)
4 Times per day 84 (79.25) 22 (20.75) 1.00 1.00
Getting the medications
Free of charge 111 (59.7) 75 (40.3) 1.00 1.00
Self-buy 94 (54.65) 78 (45.35) 1.23 (0.81, 1.87) 0.30 (0.10, 0.93)*
AOR adjusted odds ratio, COR crude odds ratio, ETB Ethiopian Birr (one U.S. dollar ≈ 21.05 ETB during the period of data collection)
*Statistically Significant at p < 0.05
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Conclusion
The study has identified the adherence level to the pre-
scribed ocular hypotensive agents to be sub-optimal ac-
cording to the Morisky Medication Adherence Scale-8,
and influenced by different factors among glaucoma pa-
tients of the public tertiary center. We recommend glau-
coma care providers to pay due attention to the
importance of adherence and influencing factors to the
prescribed medications.
Abbreviations
AOR, adjusted odds ratio; CI, confidence interval; COR, crude odds ratio;
IOP, intraocular pressure; MMAS – 8, Morisky Medication Adherence Scale – 8;
SD, standard deviation
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